Britain and America have agreed to a landmark commercial pact that will guarantee zero duties on UK medicine products entering the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to boost funding on medicines through the National Health Service (NHS). This commitment secures that import taxes on these vital exports will be held at zero for a timeframe of 36 months.
This development follows recent statements to significantly raise duties on branded pharmaceutical imports, with increases mentioned as high as one hundred percent.
"This deal with the UK reinforces the international landscape for innovative medicines and establishes much-needed equity to transatlantic medicine commerce," an announcement said.
Economic Significance
Medicines are one of the Britain's largest export categories to the United States, which is easily the primary market for leading British pharmaceutical firms.
Export figures show that in the one-year period to the end of September, the UK shipped drugs worth over eleven billion pounds to the US. This amount made up a significant portion of all goods exports in that timeframe.
"This guarantee secures jobs, stimulates capital expenditure and paves the way for the UK to establish itself as a international leader for life sciences," a government official commented.
Key British Pledges
The pact includes several specific changes from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to raise overall health service expenditure on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The percentage drug companies must return to the NHS to stay within budget will be capped at 15%. Last year, refunds exceeded twenty percent.
Industry Background
The deal comes amid a long-running tension between the sector and the ministers over spending levels and NHS adoption.
The disagreement were intensified by assertions that US consumers were paying several times more for the equivalent treatments than consumers in the other developed nations.
Recently, several large drug company projects in the UK have been halted or cancelled, while major investments have been pledged toward American operations.
One official acknowledged that the NHS had to invest a greater share on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the past decade.
